Identifies low frequency of serious adverse events for outpatient daptomycin therapy, suggesting less intensive monitoring may be sufficient.
The optimal laboratory monitoring frequency for outpatient parenteral antimicrobial therapy-related adverse events (OPAT-AEs) during daptomycin therapy is not well defined. We identified just 6.6 OPAT-AEs per 1000 sets of weekly laboratory tests in this population, suggesting that less intensive laboratory monitoring may be reasonable in patients receiving daptomycin for OPAT.
No takes yet. Share an insight, caveat, or question.
Sunagawa et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: